Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
6
100%

Phase Distribution

6

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
6(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
80.0%
Most Advanced
Phase 1

Trials by Phase

Phase 16 (100.0%)

Trials by Status

terminated117%
unknown117%
completed467%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

NCT05319587
completedphase_1

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

NCT03388749
completedphase_1

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

NCT03315039
completedphase_1

Chemotherapy in Treating Patients With Breast Cancer

NCT00012129
terminatedphase_1

Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML

NCT00430443
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05319587Phase 1

Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Completed
NCT03388749Phase 1

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Completed
NCT03315039Phase 1

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Completed
NCT00012129Phase 1

Chemotherapy in Treating Patients With Breast Cancer

Completed
NCT00430443Phase 1

Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML

Terminated
NCT00271063Phase 1

Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6